Boston Scientific to buy remaining Bolt Medical stake for up to $664M
Release date：2025-01-09 Source：https://www.medtechdive.com/news/Boston-Scientific-acquires-Bolt-Medical-lithotripsy/736807/?utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202025-01-08%20MedTech%20Dive%20%5Bissue:69299%5D&utm_term=MedTech%20Dive Author: Susan Kelly
Dive Brief:
Boston Scientific said Wednesday it has agreed to acquire Bolt Medical, paying up to $664 million for the 74% of the cardiovascular company it does not own. The price consists of a $443 million upfront payment and up to $221 million upon achievement of regulatory milestones.
Bolt is developing a laser-based intravascular lithotripsy (IVL) platform to treat coronary and peripheral artery disease. Boston Scientific said it initially developed the concept for the Bolt IVL system, helping to establish the company in 2019, and already holds an equity stake of about 26%.
“With a large, high-growth market opportunity in IVL complementary to Boston’s existing solutions in interventional cardiology, we think the deal checks a lot of the right boxes for Boston and should be nicely accretive to growth once launched,” J.P. Morgan analyst Robbie Marcus wrote in a note to clients.
Dive Brief:
Boston Scientific said Wednesday it has agreed to acquire Bolt Medical, paying up to $664 million for the 74% of the cardiovascular company it does not own. The price consists of a $443 million upfront payment and up to $221 million upon achievement of regulatory milestones.
Bolt is developing a laser-based intravascular lithotripsy (IVL) platform to treat coronary and peripheral artery disease. Boston Scientific said it initially developed the concept for the Bolt IVL system, helping to establish the company in 2019, and already holds an equity stake of about 26%.
“With a large, high-growth market opportunity in IVL complementary to Boston’s existing solutions in interventional cardiology, we think the deal checks a lot of the right boxes for Boston and should be nicely accretive to growth once launched,” J.P. Morgan analyst Robbie Marcus wrote in a note to clients.